Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Screening For Left Ventricular Dysfunction May Have Less Value Than Thought
The value and cost-effectiveness of screening for left ventricular (LV) dysfunction remains unclear, particularly since specific, evidence-based treatments are not available for the majority of patients with preserved systolic dysfunction, reports a study in the June issue of the Journal of Cardiac Failure, published by Elsevier.

How African American Men Decide Whether Or Not To Get Prostate Cancer Screening
UroToday.com - Prostate Cancer Screening among African Americans. Our manuscript that was published in Cancer Nursing, revealed an important topic in how African American men decided whether or not to get a prostate cancer screening. This is particularly important currently due to the controversy of prostate cancer screening.
News of the day
Majority Of School Nutrition Programs Now Offer Vegetarian School Lunches
School Nutrition Association president Dr. Katie Wilson, SNS announced new data today on the widespread availability of vegetarian school lunch options. Almost two thirds of school nutrition programs now offer a vegetarian school lunch on a consistent basis, up from 22% in 2003, according to the Association"s soon to be released 2009 School Nutrition Operations Report. The availability of vegetarian school lunches in a majority of districts is consistent with the overall trend in the past five years towards more nutritious school lunches emphasizing whole grains, fruits and vegetables, and low-fat dairy. The vegetarian choices also come in spite of federal school lunch reimbursements that have not kept pace with increased food and labor costs. Dr. Wilson presented the research findings at the National Conference on Childhood Obesity in Washington, DC today.
Oncology

Positive Preclinical Data On 2 Product Candidates At ENDO 09 Presented By Versartis

Versartis, Inc., an emerging company developing novel biologics with enhanced properties for patients with metabolic diseases, presented data for its long-acting product candidates, VRS-317 (hGH-rPEG) for treatment of growth hormone deficiency and for VRS-826 (IL-1ra-rPEG) for treatment of type 1 and type 2 diabetes, at the Endocrine Society"s Annual Meeting in Washington, DC. Versartis, through a unique licensing agreement with Amunix, Inc., uses the Amunix proprietary recombinant PEGylation (rPEG) technology to extend the half-life of established biologics. The preclinical Versartis compounds have the potential for significantly less frequent dosing and fewer side effects than those products currently on the market or in development. "New half-life extension data presented for the first time confirmed our expectation that dosing can be extended from weekly to monthly for our product candidates," said Jeffrey L. Cleland, Ph.D., Founder and Chief Executive Officer of Versartis. "Our preclinical data show that VRS-317 demonstrated in vivo potency equal to daily hGH, and sustained plasma levels and pharmacodynamic responses in monkeys without toxicity. Potential benefits of VRS-317 include its stability at room temperature in a liquid formulation and the ability to dose monthly with a small gauge needle, thus increasing patient safety and convenience. VRS-317 may become "best in class" hGH therapy when our preclinical studies are confirmed in human clinical trials." "Treatment of auto-inflammation in diabetes with IL-1ra has been demonstrated to increase beta-cell responsiveness in human clinical trials," Dr. Cleland continued. "Our new approach with VRS-826 will provide a less frequently administered treatment that should have comparable safety to IL-1ra, which binds both IL-1b and IL-1a. The results from preclinical studies of VRS-317 and VRS-826 were presented in poster sessions." An Extended Half-Life Human Growth Hormone Construct for Weekly Administration hGH-rPEG Poster Board Number P1-720 Wednesday, June 10, 2009 1:30 - 3:30 pm A Long Half-Life Interleukin-1-Receptor Antagonist for the Treatment of Type 2 Diabetes Mellitus IL-1ra-rPEG Poster Board Number P1-466 Wednesday, June 10,2009 1:30 - 3:30 pm Debra Bannister Versartis, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009